Compare FEMY & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | GOVX |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4M | 3.8M |
| IPO Year | 2021 | 1996 |
| Metric | FEMY | GOVX |
|---|---|---|
| Price | $2.24 | $0.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $5.50 | $1.00 |
| AVG Volume (30 Days) | 61.0K | ★ 255.5K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,293,313.00 | ★ $2,489,145.00 |
| Revenue This Year | $105.16 | N/A |
| Revenue Next Year | $200.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.77 | N/A |
| 52 Week Low | $0.29 | $0.12 |
| 52 Week High | $6.29 | $4.40 |
| Indicator | FEMY | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 24.35 |
| Support Level | $2.02 | $0.16 |
| Resistance Level | $3.21 | $0.86 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 1.15 | 3.33 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.